WUHAN, Hubei, China, May 6 /Xinhua-PRNewswire-FirstCall/ -- Benda
Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based
pharmaceutical company producing both Gendicine(R), a commercialized gene
therapy medicine for the treatment of cancer, and traditional Chinese and
conventional medicines, today filed an amendment to the Company's Form S-1
application with the Securities and Exchange Commission ("SEC"). The
amendment covers the resale by selling stockholders of up to 17,880,936
shares of common stock, $.001 par value, which includes:
1. 2,106,561 shares of common stock; and
2. 15,774,375 shares of common stock based on 150% of the common stock
issuable upon exercise of outstanding warrants issued at an exercise
price of $0.555 per share in conjunction with the private placements
completed on November 15, 2006 and April 5, 2007.
Mr. Charles Wan, Chief Executive Officer of Benda Pharmaceutical, stated, "We are pleased to file the amendment which takes us one step further to completing our S-1 registration."
Additional information regarding this registration can be found in the Company's Registration Statement on Form S-1/A, as filed with the SEC on May 5, 2008, which can be viewed at http://www.sec.gov .
About Benda Pharmaceutical, Inc.
Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.
Safe Harbor Statement
The information contained herein includes forward-looking statements.
These statements relate to future events or to our future financial
performance, and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of acti
|SOURCE Benda Pharmaceutical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved